#nasdaq:idxg

[marketexclusive]

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement Item 1.01Entry into a Material Definitive Agreement. Effective January 3, 2017, Interpace Diagnostics Group, Inc. (the Company) entered into an amended and restated placement agency agreement (the Amended Placement Agreement) with Maxim Group LLC (the Placement Agent) to which the Placement…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events Item 8.01Other Events As previously disclosed in Amendment No. 1 to its Current Report on Form 8-K/A filed on January 5, 2017, Interpace Diagnostics Group, Inc. (the Company) announced a registered direct public offering of 630,000 shares of the Companys common stock, par value $0.01 per share (the Common Stock), at a price…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Other Events Item 8.01Other Events As previously disclosed in Amendment No. 1 to its Current Report on Form 8-K/A filed on January 5, 2017, Interpace Diagnostics Group, Inc. (the Company) announced a registered direct public offering of 630,000 shares of the Companys common stock, par value $0.01 per share (the Common Stock), at a price…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Other Events Item 8.01Other Events As previously disclosed in a Current Report on Form 8-K filed on December 19, 2016, Interpace Diagnostics Group, Inc. (the Company) announced a registered direct public offering of 2,000,000 shares of the Companys common stock, par value $0.01 per share (the Common Stock), at a price of $0.53 per share and…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement Item 1.01 of the Original 8-K. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. This information is not deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Entry into a Material Definitive Agreement Item 1.01 of the Original 8-K. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. This information is not deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group Inc (NASDAQ:IDXG) Files An 8-K

Interpace Diagnostics Group Inc (NASDAQ:IDXG) Files An 8-K

James Early was appointed as the Chief Financial Officer of Interpace Diagnostics Group Inc (NASDAQ:IDXG). Mr. Early, age 62, will serve as the Company’s principal financial officer and principal accounting officer. Since August 29, 2016, the Company had engaged Mr. Early as a consultant to perform the role of interim chief financial officer. Mr. Early previously served as the Interim and…

View On WordPress

[marketexclusive]

Interpace Diagnostics Group Inc (NASDAQ:IDXG) Files An 8-K

Interpace Diagnostics Group Inc (NASDAQ:IDXG) Files An 8-K

As previously disclosed on October 4, 2016, Heinrich Dreismann, Ph.D., resigned as a member of the Board of Directors of Interpace Diagnostics Group Inc (NASDAQ:IDXG) effective as of September 30, 2016. In connection with Dr. Dreismann’s resignation and to comply with Nasdaq Listing Rule 5605(c)(4)(B), on October 5, 2016, the Company notified The Nasdaq Stock Market LLC (“NASDAQ”) that, as a…

View On WordPress